Pfizer

A surface modifying coating for an article that includes a first component having a surface in frictional engagement with a surface of a second component. At least a portion of a surface of one of the components is coated with a coating including a mixture of at least two silicones: (i) a hydrolyzable organopolysiloxane with a viscosity of less than or equal to 1,000 centistokes and that is capable of crosslinking reaction upon exposure to moisture at ambient temperature; and (ii) a second organopolysiloxane copolymerizable with the first hydrolyzable organopolysiloxane and having viscosity of greater than or equal to 5,000 centistoke; wherein the coating provides a maximum break loose force equal to or less than three times a kinetic extrusion force such that stiction is reduced between engaged surfaces. The coating is compatible with high-temperature sterilization methods sometimes used on articles for medical uses, is resistant to leaching, migration and breakdown during long-term aging conditions, and does not require a catalyst, crosslink agent, or additional energy source for preparation or application.

The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.

Method for treating vitiligo, including active and stable non-segmental vitiligo, using compounds and analogues which inhibit certain kinases including Janus Kinase (JAK), said method comprising the step of administering to the subject in need thereof 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one, or a pharmaceutically acceptable salt thereof.

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …